Related Experiment Video
Updated: Nov 21, 2025
Visualizing Mitophagy with Fluorescent Dyes for Mitochondria and Lysosome
Published on: November 30, 2022
Inhibition of mitochondrial complex II in neuronal cells triggers unique pathways culminating in autophagy with
Sathyanarayanan Ranganayaki1, Neema Jamshidi2, Mohamad Aiyaz3
1Department of Neurochemistry, National Institute of Mental Health and Neurosciences (NIMHANS), No. 2900, Hosur Road, Bangalore, Karnataka, 560029, India.
Abstract:
Mitochondrial dysfunction and neurodegeneration underlie movement disorders such as Parkinson's disease, Huntington's disease and Manganism among others. As a corollary, inhibition of mitochondrial complex I (CI) and complex II (CII) by toxins 1-methyl-4-phenylpyridinium (MPP+) and 3-nitropropionic acid (3-NPA) respectively, induced degenerative changes noted in such neurodegenerative diseases. We aimed to unravel the down-stream pathways associated with CII inhibition and compared with CI inhibition and the Manganese (Mn) neurotoxicity. Genome-wide transcriptomics of N27 neuronal cells exposed to 3-NPA, compared with MPP+ and Mn revealed varied transcriptomic profile. Along with mitochondrial and synaptic pathways, Autophagy was the predominant pathway differentially regulated in the 3-NPA model with implications for neuronal survival. This pathway was unique to 3-NPA, as substantiated by in silico modelling of the three toxins. Morphological and biochemical validation of autophagy markers in the cell model of 3-NPA revealed incomplete autophagy mediated by mechanistic Target of Rapamycin Complex 2 (mTORC2) pathway. Interestingly, Brain Derived Neurotrophic Factor (BDNF), which was elevated in the 3-NPA model could confer neuroprotection against 3-NPA. We propose that, different downstream events are activated upon neurotoxin-dependent CII inhibition compared to other neurotoxins, with implications for movement disorders and regulation of autophagy could potentially offer neuroprotection.
Insights
Mitochondrial dysfunction in neurodegenerative diseases like Parkinson's is linked to complex II inhibition. Autophagy regulation and Brain Derived Neurotrophic Factor (BDNF) show potential for neuroprotection against 3-NPA toxicity.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Mitochondrial dysfunction is a key factor in neurodegenerative movement disorders.
- Toxins inhibiting mitochondrial complex I (MPP+) and complex II (3-NPA) induce disease-relevant neuronal damage.
- Understanding downstream pathways of specific mitochondrial complex inhibition is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the distinct downstream molecular pathways activated by complex II inhibition (3-NPA) compared to complex I inhibition (MPP+) and manganese neurotoxicity.
- To identify novel pathways involved in neuronal survival and death following complex II inhibition.
- To explore the role of autophagy and Brain Derived Neurotrophic Factor (BDNF) in the context of 3-NPA-induced neurotoxicity.
Main Methods:
- Genome-wide transcriptomics (RNA-seq) of N27 neuronal cells exposed to 3-NPA, MPP+, and Manganese.
- In silico modeling to compare toxin-induced pathway alterations.
- Morphological and biochemical analysis of autophagy markers.
- Assessment of mechanistic Target of Rapamycin Complex 2 (mTORC2) pathway activity.
- Measurement of Brain Derived Neurotrophic Factor (BDNF) levels.
Main Results:
- 3-NPA exposure resulted in a unique transcriptomic profile compared to MPP+ and Manganese, with autophagy being a predominant differentially regulated pathway.
- Autophagy was found to be incomplete and mediated by the mTORC2 pathway in the 3-NPA model.
- Elevated levels of BDNF were observed in the 3-NPA model, suggesting a potential neuroprotective role.
- Distinct downstream events are activated by neurotoxin-dependent complex II inhibition compared to other neurotoxins.
Conclusions:
- Complex II inhibition by 3-NPA uniquely impacts cellular pathways, particularly autophagy, suggesting specific mechanisms in neurodegeneration.
- Modulation of autophagy and enhancement of BDNF signaling may offer therapeutic strategies for movement disorders linked to mitochondrial dysfunction.
- Targeting the mTORC2 pathway and leveraging BDNF's neuroprotective effects could be promising avenues for treating neurodegenerative conditions.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:27Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
01:36Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
01:30The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...